Last reviewed · How we verify
BX-1
BX-1 is a herbal extract combination that modulates immune and inflammatory pathways to support respiratory and immune function.
BX-1 is a herbal extract combination that modulates immune and inflammatory pathways to support respiratory and immune function. Used for Respiratory tract infections or related respiratory conditions (specific indication not publicly detailed).
At a glance
| Generic name | BX-1 |
|---|---|
| Sponsor | Bionorica SE |
| Drug class | Herbal/Phytopharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Immunology |
| Phase | Phase 3 |
Mechanism of action
BX-1 is a phytopharmaceutical product developed by Bionorica SE, typically composed of standardized plant extracts. The mechanism involves modulation of innate immune responses and reduction of inflammatory mediators relevant to respiratory conditions. Bionorica's products generally work through multiple bioactive compounds that enhance mucosal immunity and reduce airway inflammation.
Approved indications
- Respiratory tract infections or related respiratory conditions (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (PHASE2)
- Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (PHASE3)
- BX-1 in Spasticity Due to Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BX-1 CI brief — competitive landscape report
- BX-1 updates RSS · CI watch RSS
- Bionorica SE portfolio CI